How is adipotide different from GLP-1 drugs like semaglutide?

Completely different mechanism. GLP-1 drugs reduce appetite and slow gastric emptying. Adipotide physically destroys the blood supply to fat tissue, causing fat cells to die from lack of nutrients. It doesn't affect appetite or metabolism — it directly eliminates fat tissue vasculature.

Why was adipotide development stopped?

Dose-dependent kidney toxicity was observed in primate studies — elevated serum creatinine, glucosuria, proteinuria, and tubular degeneration. While the kidney damage was reversible within 28 days of stopping treatment, the therapeutic window (effective fat loss dose vs. kidney-toxic dose) was too narrow for safe clinical use.

Is adipotide available?

Adipotide is not FDA-approved, not in clinical trials, and not available through legitimate medical channels. It circulates in the gray market research peptide space, but its kidney toxicity profile makes unsupervised use particularly dangerous.

Adipotide

An experimental fat-targeting peptide that selectively destroys blood vessels feeding white adipose tissue. Produced dramatic fat loss in primate studies but was discontinued due to kidney toxicity.

PreliminaryUse Caution

What is Adipotide?

Adipotide (FTPP) is a synthetic chimeric peptide composed of two functional domains: a cyclic targeting motif (CKGGRAKDC) that selectively binds prohibitin on endothelial cells in white adipose tissue vasculature, fused to D(KLAKLAK)2, a peptidomimetic sequence that disrupts mitochondrial membranes upon internalization. Rather than acting on fat cells directly, adipotide destroys the blood vessels that supply fat tissue, depriving adipocytes of oxygen and nutrients. It produced striking fat loss results in obese primates — up to 39% body fat reduction — but clinical development was discontinued after dose-dependent, reversible kidney toxicity was observed.

Why People Talk About It

Targeted white adipose tissue destruction

Preliminary

Rapid fat loss in primate models

Preliminary

Insulin resistance improvement

Preliminary

How It Works

Adipotide works like a guided missile for fat tissue. One part of the peptide finds and locks onto blood vessels that specifically feed fat deposits. The other part punches holes in those blood vessel cells, destroying them. Without blood supply, the fat tissue starves and shrinks. The problem is that the "missile" can also hit kidney blood vessels, causing damage.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Dose-dependent kidney toxicity (elevated creatinine, tubular degeneration)Glucosuria and proteinuriaIncreased epithelial cells in urine

Cautions

• Clinical development was discontinued due to kidney toxicity
• Narrow therapeutic window between effective and toxic doses
• Not FDA-approved and not in clinical trials
• Gray market sources have unknown purity and composition
• Should NOT be self-administered — kidney damage risk is real and documented

What We Don't Know

No human clinical data exists. The kidney toxicity observed in primates was reversible within 28 days, but long-term effects of repeated exposure are unknown. Whether a safer dosing regimen could preserve efficacy while avoiding renal damage has not been explored.

Published Research

3 studies

Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium.

PreclinicalPMID: 22733798

A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys.

Preclinical

Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium Reduces Food Intake and Body Weight.

Preclinical

Mechanism of Action

Adipotide is a chimeric peptide with two functional domains. The N-terminal cyclic motif CKGGRAKDC binds to prohibitin, a receptor selectively expressed on the surface of endothelial cells in white adipose tissue vasculature. Upon receptor-mediated internalization, the C-terminal D(KLAKLAK)2 domain — a synthetic sequence composed entirely of D-amino acids for protease resistance — disrupts mitochondrial membranes, triggering apoptosis in the target endothelial cells. The resulting vascular destruction deprives white adipose tissue of blood supply, leading to adipocyte death and resorption. In obese rhesus macaques, this mechanism produced a 38.7% reduction in total body fat (DEXA-confirmed) and a 36.2% decrease in insulin AUC over 28 days at 0.43 mg/kg/day. The kidney toxicity results from prohibitin expression in renal proximal tubular cells, where adipotide causes off-target tubular degeneration and single-cell necrosis.

Evidence Snapshot

Overall Confidence35%

Human Clinical Evidence

None. Adipotide has never been tested in human clinical trials. Development was discontinued at the preclinical stage due to kidney toxicity in primates.

Animal / Preclinical

Strong within primates. A study in 39 rhesus macaques, 2 baboons, and 52 cynomolgus monkeys demonstrated dose-dependent weight loss (up to 20.4% body weight), 38.7% total body fat reduction, and significant improvement in insulin resistance (48.5% reduction in insulinogenic index). MRI and DEXA confirmed white adipose tissue volume decreases. However, dose-dependent renal tubular injury was observed at therapeutic doses, reversible within 28 days post-treatment.

Mechanistic Rationale

Strong. The vascular targeting mechanism is well-characterized: prohibitin binding, endothelial cell internalization, mitochondrial membrane disruption, and subsequent adipose tissue ischemia. The off-target kidney toxicity is also mechanistically understood (prohibitin expression in renal tubules). Published in Science Translational Medicine.

Forms & Administration

Adipotide was administered via daily subcutaneous injection in primate studies at 0.43 mg/kg. It is not approved for human use and is not available through legitimate medical channels. Due to documented kidney toxicity, this peptide should not be self-administered under any circumstances.

Use Cases & Evidence Levels

Targeted white adipose tissue destruction

Preliminary30%

Rapid fat loss in primate models

Preliminary30%

Insulin resistance improvement

Preliminary30%

Safety Profile

Safety Information

Common Side Effects

Dose-dependent kidney toxicity (elevated creatinine, tubular degeneration)Glucosuria and proteinuriaIncreased epithelial cells in urine

Cautions

• Clinical development was discontinued due to kidney toxicity
• Narrow therapeutic window between effective and toxic doses
• Not FDA-approved and not in clinical trials
• Gray market sources have unknown purity and composition
• Should NOT be self-administered — kidney damage risk is real and documented

What We Don't Know

Published Research

3 studies

Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium.

PreclinicalPMID: 22733798

A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys.

Preclinical

Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium Reduces Food Intake and Body Weight.

Preclinical

Related Peptides

AOD-9604

EmergingBeginner

A modified fragment of human growth hormone studied specifically for fat metabolism without the growth-promoting effects of full GH.

Semaglutide

StrongBeginner

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.

Tirzepatide

StrongBeginner

A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.

Quick Facts

Class: Proapoptotic Peptide
Evidence: Preliminary
Safety: Use Caution
Updated: Apr 2026
Citations: 3PubMed

Also known as

FTPPFat-Targeted Proapoptotic PeptideProhibitin-Targeting Peptide

Evidence Score

Overall Confidence35%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.